Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
formoterol · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| formoterol | DEVICE | - |
Inclusion Criteria: * Patients who are capable of understanding the directions for device usage, evaluating device function and completing the patient diary * Patients who have a current diagnosis of asthma * Patients who have a documented forced expiratory volume at 1 second (FEV1) reversibility o...
Formoterol is an investigational small molecule being studied for the treatment of asthma. It is a bronchodilator intended to help manage asthma symptoms. The drug is currently in clinical development, with completed trials evaluating its use in patients with asthma, including studies on device functionality and dose equivalence.
Formoterol is being developed by Novartis AG, a global healthcare company traded on the New York Stock Exchange under the ticker symbol NVS. The company has conducted clinical trials to evaluate the drug's use in asthma, including studies on inhalation devices and dose equivalence.
Formoterol is in Phase 3 clinical development for asthma. While one trial is listed as Phase 3, another is Phase 2. The drug is investigational and has not been approved by regulatory authorities. All completed trials have finished, and no active trials are currently listed.
Formoterol has been studied in two completed clinical trials. NCT00130351 was a Phase 3 study in the United States with 155 participants, examining patient use and functionality of formoterol in a novel inhalation device for asthma. NCT00443482 was a Phase 2 study in Germany with 50 participants, demonstrating equivalence of formoterol 12 and 24 µg delivered via two dry powder inhalers.
Formoterol is a specific drug being developed by Novartis. It is a long-acting bronchodilator used in asthma treatment. While it belongs to a class of medications known as beta-2 agonists, the data provided does not list alternative names for this specific drug. It is being studied for its efficacy and device compatibility in asthma patients.